RT Journal Article
SR Electronic
T1 First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 248
OP 251
DO 10.2967/jnumed.115.167361
VO 57
IS 2
A1 Ken Herrmann
A1 Margret Schottelius
A1 Constantin Lapa
A1 Theresa Osl
A1 Andreas Poschenrieder
A1 Heribert Hänscheid
A1 Katharina Lückerath
A1 Martin Schreder
A1 Christina Bluemel
A1 Markus Knott
A1 Ulrich Keller
A1 Andreas Schirbel
A1 Samuel Samnick
A1 Michael Lassmann
A1 Saskia Kropf
A1 Andreas K. Buck
A1 Hermann Einsele
A1 Hans-Juergen Wester
A1 Stefan Knop
YR 2016
UL http://jnm.snmjournals.org/content/57/2/248.abstract
AB Chemokine receptor 4 (CXCR4) is a key factor for tumor growth and metastasis in several types of human cancer. Based on promising experiences with a radiolabeled CXCR4 ligand (68Ga-pentixafor) for diagnostic receptor targeting, 177Lu- and 90Y-pentixather were recently developed as endoradiotherapeutic vectors. Here, we summarize the first-in-human experience in 3 heavily pretreated patients with intramedullary and extensive extramedullary manifestations of multiple myeloma undergoing CXCR4-directed endoradiotherapy. Methods: CXCR4 target expression was demonstrated by baseline 68Ga-pentixafor PET. Each treatment was approved by the clinical ethics committee. Pretherapeutic 177Lu-pentixather dosimetry was performed before 177Lu-pentixather or 90Y-pentixather treatment. Subsequently, patients underwent additional chemotherapy and autologous stem cell transplantation for bone marrow rescue. Results: A remarkable therapeutic effect was visualized in 2 patients, who showed a significant reduction in 18F-FDG uptake. Conclusion: CXCR4-targeted radiotherapy with pentixather appears to be a promising novel treatment option in combination with cytotoxic chemotherapy and autologous stem cell transplantation, especially for patients with advanced multiple myeloma.